Document Detail

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
MedLine Citation:
PMID:  24292815     Owner:  NLM     Status:  MEDLINE    
The purpose of this study is to evaluate the efficacy and safety of docetaxel plus cyclophosphamide(TC) compared with docetaxel, anthracycline, and cyclophosphamide(TEC) in neoadjuvant treatment of triple negative or HER2 positive breast cancer. Eligible breast cancer patients were randomized to receive six cycles of TC or TEC. The primary end point was pathological complete remission (pCR). Secondary end points included safety, clinical response rate, and survival outcome. One hundred and two patients were initially randomized and 96 patients were available for efficacy analysis. 96.9 % patients were treated with epirubicin as an anthracycline agent. pCR rates were 6.8 % (3/45) and 17.6 % (9/51) in TC and TEC group, respectively, P = 0.113. After a mean follow up of 20 (3–36) months, non-anthracycline-containing TC regimen treatment resulted in a worse event free survival (adjusted hazard ratio [HR] 2.42; 95 % CI1.11–5.30) and disease-free survival (HR 2.85; 95 % CI1.21–6.74) compared with TEC regimen, which was more apparent in triple negative subtype. Severe adverse event rates were similar, except that patients treated with TEC had a higher rate of neutropenia and leucopenia. TEC treatment had a superior survival outcome and trend of higher pCR rate compared with TC in this trial setting, especially in triple negative subtype, which deserves further validation.
Xiaosong Chen; Guolin Ye; Chenfang Zhang; Xinzheng Li; Yiding Chen; Xiaohong Xie; Hong Zheng; Yali Cao; Kejin Wu; Duo Ni; Jinhai Tang; Ziguo Wei; Kunwei Shen
Related Documents :
24785185 - Physical and psychological implications in a multiple and preterm caesarean section a c...
10612345 - Characteristics of a unique visual field defect attributed to vigabatrin.
7611945 - Electroencephalography in congenital malformations of the central nervous system.
17548985 - Anticonvulsants during electroconvulsive therapy: review and recommendations.
22272565 - Distended bladder presenting with constipation and venous obstruction: a case report.
17172395 - Evaluation of three rapid tests for diagnosis of p. falciparum and p. vivax malaria in ...
Publication Detail:
Type:  Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  142     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-09     Completed Date:  2014-07-18     Revised Date:  2014-08-18    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  549-58     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Breast Neoplasms / drug therapy*,  metabolism,  mortality,  pathology
Cyclophosphamide / administration & dosage,  adverse effects,  therapeutic use
Etoposide / adverse effects,  therapeutic use
Lymphatic Metastasis
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Receptor, erbB-2 / metabolism
Taxoids / administration & dosage,  adverse effects,  therapeutic use
Treatment Outcome
Triple Negative Breast Neoplasms / drug therapy*,  mortality,  pathology
Reg. No./Substance:
0/Taxoids; 15H5577CQD/docetaxel; 6PLQ3CP4P3/Etoposide; 8N3DW7272P/Cyclophosphamide; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Next Document:  Multiscale immunomagnetic enrichment of circulating tumor cells: from tubes to microchips.